Cost of renal replacement therapy

Nephrology Dialysis Transplantation

Volumn 28, Issue 10, 2013, Pages 2399-2401

  Rosner, Mitchell H ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEMODIALYSIS; KIDNEY FAILURE; MEDICAL DECISION MAKING; PERITONEAL DIALYSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; RENAL REPLACEMENT THERAPY;

HUMANS; KIDNEY DISEASES; PERITONEAL DIALYSIS; RENAL DIALYSIS; WORLD HEALTH;

EID: 84884935354     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft274     Document Type: Article

References (15)

1. Folland S, Goodman AC, Stano M. Chapter 4: economic efficiency and cost-benefit analysis. In: The Economics of Health and Health Care. 6th edn. Boston, MA: Prentice Hall, 2010
2. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health 2009; 12(Suppl 1): S5-S9
3. Nayak A, Mason G, Rettore E et al. Cost of peritoneal dialysis and hemodialysis across the world. Nephrol Dial Transplant 2013; 28: 2553-2569
4. Mehrotra R, Chiu YW, Kalantar-Zadeh K et al. Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in the United States. Arch Intern Med 2011; 171: 110-118
5. Weinhandl ED, Foley RN, Gilbertson DT et al. Propensitymatched mortality comparison of incident hemodialysis and peritoneal dialysis patients. J Am Soc Nephrol 2010; 21: 499-506
6. Jiwakanon S, Chiu YW, Kalantar-Zadeh K et al. Peritoneal dialysis: an underutilized modality. Curr Opin Nephrol Hypertens 2010; 19: 573-577
7. US Renal Data System, USRDS 2012 Annual Data Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012
8. Churchill DN, Torrance GW, Taylor DW et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med 1987; 10: 14-20 (Pubitemid 17038999)
9. Just PM, Riella MC, Tschosik EN et al. Economic evaluations of dialysis treatment modalities. Health Policy 2008; 86: 163-180
10. Fong E, Bargman JM, Chan CT. Cross-sectional comparison of quality of life and illness intrusiveness in patients who are treated with nocturnal home hemodialysis versus peritoneal dialysis. Clin J Am Soc Nephrol 2007; 2: 1195-1200
11. McFarlane PA, Bayoumi AM, Pierratos A et al. The quality of life and cost utility of home nocturnal and conventional incenter hemodialysis. Kidney Int 2003; 64: 1004-1011 (Pubitemid 37013836)
12. Lee CP, Zenios SA, Chertow GM. Cost-effectiveness of frequent in-center hemodialysis. J Am Soc Nephrol 2008; 19: 1792-1797
13. Tennankore KK, Chan CT, Curran SP. Intensive home hemodialysis: benefits and barriers. Nat Rev Nephrol 2012; 8: 515-522
14. Chow KM, Li PK-T. Dialysis: choice of dialysis-what to do with economic incentives. Nat Rev Nephrol 2012; 8: 495-496
15. Institute on Medicine. Initial Priorities for Comparative Effectiveness Research. Board on Health Care Services. Washington, DC: The National Academies Press, 2009